Therapy Areas: Inflammatory Diseases
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
9 September 2026 - Altesa BioSciences, a clinical-stage pharmaceutical company focused on chronic lung diseases including COPD and asthma, announced on Tuesday new clinical data showing that its inves...
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
4 September 2026 - Kali Therapeutics, a clinical-stage biotechnology company focused on new therapies for autoimmune and inflammatory diseases, announced on Thursday that the US Food and Drug Administ...
Teva reports positive Phase 2a data for TEV '408 in celiac disease
2 September 2026 - Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on Wednesday reported positive top-line results from an ongoing Phase 2a study of TEV &...
AbbVie seeks EMA approval for subcutaneous induction of risankizumab in Crohn's disease
27 August 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) announced on Thursday that it has applied to the European Medicines Agency for approval of subcutaneous induction dosing of SKYRIZI (r...
AstraZeneca and Amgen report Tezspire met primary endpoints in Phase III EoE trial
27 August 2026 - Biopharmaceutical companies AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Amgen Inc (NASDAQ:AMGN) on Thursday reported positive results from the Phase III CROSSING trial showing ...
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
27 August 2026 - Swedish clinical-stage biotech company Oxcia AB, which develops therapies targeting oxidative stress and DNA damage response pathways, announced on Thursday that the European Medicine...